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Malignant gliomas carry a dismal prognosis. Conventional treatment using
chemo- and radiotherapy has limited efficacy with adverse events. Therapy with
genetically engineered T-cells, such as chimeric antigen receptor (CAR) T-cells, may
represent a promising approach to improve patient outcomes owing to their potential
ability to attack highly infiltrative tumors in a tumor-specific manner and possible
persistence of the adaptive immune response. However, the unique anatomical
features of the brain and susceptibility of this organ to irreversible tissue damage
have made immunotherapy especially challenging in the setting of glioma. With safety
concerns in mind, multiple teams have initiated clinical trials using CAR T-cells in glioma
patients. The valuable lessons learnt from those trials highlight critical areas for further
improvement: tackling the issues of the antigen presentation and T-cell homing in
the brain, immunosuppression in the glioma microenvironment, antigen heterogeneity
and off-tumor toxicity, and the adaptation of existing clinical therapies to reflect the
intricacies of immune response in the brain. This review summarizes the up-to-date
clinical outcomes of CAR T-cell clinical trials in glioma patients and examines the most
pressing hurdles limiting the efficacy of these therapies. Furthermore, this review uses
these hurdles as a framework upon which to evaluate cutting-edge pre-clinical strategies
aiming to overcome those barriers.
Keywords: T lymphocyte, brain cancer, Glioblastoma, TCR - T cell receptor, CAR (chimeric antigen receptor) T
cells, Glioma
INTRODUCTION
Malignant gliomas, including glioblastoma (GBM), are the most common form of malignant
primary brain tumors. Among those, GBM represents the most common and aggressive tumors
with an average survival rate of 15 months following diagnosis (1). The current standard of
care involves maximal safe tumor resection followed by radiotherapy and chemotherapy. Despite
advances in cytotoxic therapy regimens, targeted angiogenesis inhibitors and novel therapeutic
modalities, such as alternating electric field therapy, patient survival has only improved modestly
over recent years (2). GBM may occur de novo in multiple types of neuro-epithelial cells, which is
diagnosed as primary GBM, or it may arise following the progression or recurrence of low-grade
glioma (LGG) into high grade form (HGG), in which case it is diagnosed as secondary GBM.
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Primary GBM is more prevalent, confers worse prognosis,
and is understood to develop from distinct genetic precursors
compared to secondary GBM (3). In addition to the distinction
between primary and secondary GBM, malignant gliomas
represent the most common mortality and morbidity among
pediatric cancers. Especially, high grade gliomas that affect the
midline structure of the brain [diffuse midline gliomas (DMG)]
are among the poorest responders to existing treatments, due
in part to the unique genetic and epigenetic mechanisms
driving the development of these tumors (4). The wide
differences in tumor etiology and genetic landscape among GBM
necessitate different treatment approaches and have resulted
in a patient population with an acute need for improved
therapy.
The central nervous system (CNS) was once considered an
immune privileged site that was spared from the potentially
damaging effects of active immune responses (5, 6). However,
decades of research into the role of the immune system
within the CNS has amended this preconception and allowed
for a deeper understanding of how the adaptive immune
response can function in the CNS [reviewed in (7)]. Recent
studies investigating peptide vaccines and adoptive cell transfer
for patients with malignant glioma have demonstrated that
systemically administered treatments can, in fact, elicit antigen-
specific T-cell responses. Despite these encouraging data,
however, therapeutic responses were observed infrequently and
had variable durations (8–12). The results of these initial trials
underscore the need for continued in-depth research and analysis
of the immunotherapeutic approaches for the treatment of
glioma patients.
The successes of chimeric antigen receptor (CAR) T-cell
therapy in hematological cancers have renewed the hope that
durable remissions may become possible for patients with solid
cancers, including those with GBM. Brain tumor patients have
proven to be a particularly challenging population to treat with
immunotherapy as many of the characteristics of a productive
immune response, such as edema and widespread inflammatory
infiltration, can have a devastating effect when they occur
within close proximity to neural tissues. Despite these increased
risks, genetically engineered T-cells, such as CAR T-cells, have
the potential to improve the survival outcomes for patients.
Tumor-targeting CARs are genetically engineered receptors that
combine the antigen specificity of antibodies through the use of
single chain variable fragments (scFv) with the potent antitumor
effects of activated T-cells (13). However, the use of antibody-
derived scFv limits antigen selection to surface bound proteins.
Therefore, multiple groups, including ours, have begun to
evaluate genetically engineered T-cells expressing a physiological
form of tumor antigen-reactive T-cell receptor (TCR) in patients
where tumor-specific neoantigens are derived from intracellular
proteins (14). Regardless of the mode of antigen recognition,
genetically engineered T-cell therapy in brain tumor patients
has encountered a panoply of challenges. Some of these hurdles
may be shared among all solid tumor types, such as antigen
heterogeneity and tumor-derived immunosuppression, while
other challenges are characteristic to CNS malignancies, such
as the absence of professional antigen-presenting cells and the
limitations to lymphocyte homing resulting from the blood-brain
barrier.
In this review, we will highlight the most recent clinical
status of CAR T-cell therapy for malignant glioma and then
discuss the major challenges facing CAR T-cell immunotherapy
in GBM, including neuroanatomical considerations, barriers
to effector T-cell trafficking, immunosuppression in the GBM
microenvironment, antigen heterogeneity, off-tumor toxicity,
as well as the diverse challenges and opportunities afforded
by concomitant therapies in the clinic. Furthermore, we will
use these challenges as a framework to evaluate strategies for
engineering more effective and specific CAR T-cell therapies for
glioma.
CLINICAL EXPERIENCES WITH GBM CAR
T-CELL THERAPY
The clinical utility of CAR T-cells targeting CD19 in relapsed and
refractory B cell malignancies has proven to be exceptional in
these patient populations (15, 16). However, the efficacy of CAR-
T therapy in solid tumors has been less evident (17). Despite the
complex barriers associated with treating CNS cancers, several
early phase CAR T-cell clinical studies provide encouraging data.
GBM-Specific CAR T-Cell Targets
GBM are generally considered to be immunologically cold
tumors due in part to the overall low mutation loads of these
tumor cells (18). One of the key challenges that has impeded
development of CAR therapies for GBM is the limited availability
of targetable tumor-specific antigens which do not confer any
risk of toxicity toward normal tissues. An attractive mutation
resulting in the formation of a common neoantigen in the GBM
context is variant III of the epidermal growth factor receptor
(EGFRvIII). This truncated receptor is expressed in 20% of
newly diagnosed GBM patients and has not been found to be
expressed on normal tissues, rendering it tumor-specific (19–21).
It is characterized by an in-frame deletion of exons 2–7, which
confers ligand-independent constitutive signaling through EGFR
that results in cellular proliferation and enhanced resistance to
both radio- and chemotherapies. The generation of a glycine at
the splice-junction between exons 1-8 provides a surface epitope
that can be readily targeted by immunotherapeutic approaches
(21).
In a phase I clinical trial, O’Rourke and colleagues treated
10 recurrent GBM patients with a single intravenous infusion of
autologous EGFRvIII-specific CAR T-cells. The group observed
no objective radiographic response, apart from one patient who
presented with stable residual disease for over 18 months. The
patients did not suffer any off-tumor toxicities or cytokine
release syndrome, providing evidence that systemic infusion of
EGFRvIII-CAR T-cells is feasible and safe (12). Importantly,
the authors observed significant but transient expansion of the
CAR T-cells during the course of treatment and successful
infiltration of CAR T-cells in the tumor site, which was ultimately
associated with the decrease of EGFRvIII-expressing tumor cells.
In addition, the research team noted increased and robust
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upregulation of several immune inhibitory molecules, such as
programmed death ligand receptor-1 (PD-L1) and indoleamine-
2,3-deoxygenase 1 (IDO1). The presence of CAR T-cells at the
tumor site is evidence that systemically infused T-cells can be
activated and recruited to the brain. While these observations
are encouraging, the failure of this therapy to achieve objective
clinical responses underscores the potentially debilitating impact
of antigen heterogeneity and local immune suppression on CAR
therapy which often manifests in the outgrowth of antigen loss
variants.
GBM-Associated CAR T-Cell Targets
IL-13 receptor α2 (IL-13Rα2) is a promising non-mutant GBM-
associated antigen due to its broad tumor expression and
extremely low expression levels in normal brain (22). This
monomeric high affinity receptor binds IL-13 but not IL-4 and
drives the production of transforming growth factor-β (TGF-
β) in the tumor microenvironment (TME) (23). IL-13Rα2 is
overexpressed in 75% of GBM patients and is a prognostic
indicator for poor patient survival (24). Initial studies by Brown
et al. evaluated the effect of repeated intracranial injections
of IL13Rα2-targeting CD8+ CAR T-cells in 3 patients with
recurrent GBM (25). The treatment was well-tolerated and
resulted in transient antitumor activity in two of three patients.
However, the authors noted that residual tumor tissue adjacent
to the site of injection displayed significantly lower expression
of IL13Rα2, implying antigen loss as a result of therapy. The
same group subsequently reported a case study where they
observed regression of an IL13Rα2-positive multifocal GBM
tumor in a patient treated with intraventricular administrations
of second generation IL13Rα2-CAR T-cells that also express
CD137 intracellular domain as part of the CAR construct (26).
The authors observed transient complete response of all cranial
and metastatic tumors after repeated infusions. However, the
patient eventually succumbed tometastatic recurrent lesions with
decreased expression of IL13Rα2, highlighting the importance
of developing improved strategies for overcoming acquired
immune resistance on a systemic scale.
Another Phase I clinical trial by Ahmed et al. targeting
the tumor-associated antigen human epidermal growth factor
receptor-2 (HER2) reported the outcome of treating 17 GBM
patients with HER2-specific CAR T-cells (27). The authors
reported no serious adverse events following the administration
of dose-escalating treatments and the observation of clinical
benefit in 8 of 17 patients (1 partial response and 7 stable disease).
The autologous T-cells used to manufacture CAR T-cells in this
study were selected to be virus-specific. Because 16 of the 17
patients tested seropositive for cytomegalovirus, the investigators
hypothesized that expression of the CAR construct in virus-
specific CD8+ T-cells would optimize the persistence of CAR
T-cells if the T-cells were to receive survival and proliferation
signals via their endogenous TCR. Unfortunately, the CAR T-
cells did not expand and persisted in only low levels in the
periphery, suggesting the need to further develop methods of
enhancing CAR T-cell survival and expansion in vivo.
While the positive safety profiles reported by all four studies
are encouraging, these data highlight the substantial challenges
facing CAR T-cell therapy for GBM. One key finding from
all three recently completed Phase I studies was the low level
expansion and persistence of the infused CAR-T-cells. Variable
expansion and trafficking of T-cells to the brain tumor site, the
dynamic immunosuppressive response mounted by the TME,
and antigen loss in post-therapy recurrent tumors may explain
some of this lack of expansion and persistence. We will start by
investigating each of these sets of challenges in more detail and
then review the strategies currently being explored to address
them in the setting of malignant glioma.
NEUROANATOMICAL CHALLENGES AND
T-CELL HOMING
The efficacy of immunotherapy for malignant glioma relies
upon the ability of therapeutic immune cells to reach the
brain parenchyma and induce an anti-tumor response. Although
adaptive immunity plays a critical role in immune surveillance
of the CNS, the CNS has developed mechanisms that tightly
regulate entry and activation of innate and adaptive immune
cells to limit the potential side effects of neuroinflammation. It
is important to recognize that the effects of inflammation, such
as edema, cytokine-induced toxicity, and neurodegeneration,
can be detrimental to the functional integrity of the CNS.
Understanding of the neuroanatomical features that underlie
these mechanisms is essential for the successful development
and application of genetically engineered T-cells for malignant
glioma. The CNS was historically considered a site of immune
privilege because neither allografts transplanted in the brain
of immune- competent mice nor the inoculation of viral
and bacterial pathogens into the brain parenchyma elicited
immunological responses (5, 6, 28, 29). These findings were
initially attributed to the presence of the BBB, absence of
lymphatics, and the relative incompetence of antigen presenting
cells in the CNS. However, several decades of research into neuro-
inflammatory conditions and clinical oncology have challenged
these notions [reviewed in (7)]. It is currently understood
that the CNS is neither completely privileged from systemic
immunity nor impermeable to activated immune cells (9, 30, 31).
Nevertheless, the unique anatomical features of the CNS pose
several challenges that impede the ability of T-cells to recognize
and respond to antigens within the brain. This section discusses
these features and outlines a variety of strategies to overcome
these impediments.
Anatomical Considerations of the Immune
Response
The CNS can be broadly divided by the areas which are protected
by the BBB and those that are not, which has important
consequences for the efferent arm of the immune response.
The ventricles, meninges, and spinal cord are not protected
by the BBB and are bathed in the cerebrospinal fluid (CSF)
produced by the choroid plexus (32). The brain parenchyma
and its interstitial fluid (ISF) are anatomically separated from
both the peripheral bloodstream and the CSF by the BBB.
The brain parenchyma lacks conventional lymphatic vessels and
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instead relies upon the drainage of tumor antigens and immune
cells through the ISF and CSF into the dural, cervical, and
nasal lymphatics. Access to these peripheral lymphatics depends
upon anatomical location within the CNS. Both the cellular and
soluble components of the CSF in the ventricular and subdural
spaces can drain efficiently to the peripheral lymphatics (33–
35). However, these same components within the ISF of the
brain parenchyma are anatomically restricted from reaching the
peripheral lymphatic system. Instead, the parenchyma must rely
upon the limited exchange of CSF and ISF, termed the glymphatic
system, in order for soluble antigens and signaling molecules
to reach the peripheral lymphatics (36, 37). The absence of
conventional lymphatic access to the parenchyma greatly hinders
the afferent arm of the adaptive immune system needed for
antigen presentation and the initiation of a systemic immune
response to a tumor.
The BBB is a permeability barrier composed of tight junctions
connecting endothelial cells with the luminal and abluminal
membranes lining the capillaries of the brain (38). Although not
an absolute barrier, the BBB restricts the entry of ionic substances,
large molecules, and naïve immune cells from the peripheral
blood into the brain parenchyma. Lymphocyte entry into the
brain parenchyma is tightly regulated (Figure 1) by the BBB as
well as the glia limitans, which is formed by the fusion of astrocyte
processes lining the parenchymal basal membrane along the
entirety of the CNS (39). The BBB selectively allows activated
but not naïve T-cells to enter the brain (40–42). Therefore, in the
absence of inflammation, the brain parenchyma is largely devoid
of immune cells. However, it is important to recognize that T-
cells can cross the BBB and infiltrate the brain parenchyma given
the right circumstances (43–45).
T-Cell Recruitment to the Brain
Parenchyma
Although the infiltration of immune cells is heavily restricted,
there are a few mechanisms by which a small number of
lymphocytes and antigen presenting cells can enter the CNS:
(i) via the post-capillary venules into the perivascular space; ii)
by extravasation through the choroid plexus of the ventricles
into the CSF; or iii) through superficial leptomeningeal vessels
into the subarachnoid space (46, 47). We will discuss the
first mechanism in detail as it pertains most directly to the
recruitment of T-cells into the brain parenchyma.
Recruitment of T-cells into the brain parenchyma is a
sequential, coordinated process beginning with the binding
of integrins α4β1 and lymphocyte associated antigen-1 (LFA-
1) expressed on activated T-cells to the adhesion molecules
vascular cell adhesion molecule 1 (VCAM1) and intracellular cell
adhesion molecule 1 (ICAM1) on endothelial cells, respectively
(39). Adhesion of cells to endothelial cells of the CNS
also involves a tissue-restricted adhesion molecule, activated
leukocyte adhesion molecule (ALCAM) which binds CD6
on mature T-cells (48). The rolling of T-cells established
by these ligand-binding interactions leads to the activation
of G protein-coupled receptors on the T-cells, resulting in
conformational changes that promote tight binding of integrins
to cell adhesion molecules on the endothelium. Following these
integrin-adhesion molecule interactions, T-cells traverse through
the endothelial lining and reach the perivascular space. Activated
T-cells must then cross the glia limitans to enter the brain
parenchyma. The entry of T-cells into the brain parenchyma is
regulated by matrix metalloproteases (MMPs) secreted by other
T-cells (49). Furthermore, factors such as tumor necrosis factor-α
(TNFα), IL-12, TGFβ, and IL-6 secreted by astrocytes of the glia
limitans in an inflammatory setting additionally regulate entry
of activated T-cells across the BBB (50, 51). Similarly, increased
expression of cell adhesion molecules in malignant glioma as
well as neuro-inflammatory conditions, such as such as multiple
sclerosis (MS) and experimental autoimmune encephalomyelitis,
was shown to increase infiltration of T-cells into the brain
parenchyma (48, 52, 53). Another critical factor that dictates T-
cell recruitment into the parenchyma is antigen-specificity. Galea
et al. demonstrated that antigen specific CD8+ T-cells can traffic
to the site of the brain where cognate antigen is present, while
CD4+ T-cells can traffic across the BBB regardless of antigen
specificity (38).
Interestingly, it is clear from radiographic imaging of GBM
that these tumors regularly disrupt the BBB to an extent that
varies within tumors and between patients (54). In particular,
glioma cells have been shown to breach the BBB by decoupling
vasculature from the astrocytic endfeet that maintain BBB
integrity and potentially increase exposure of the tumor to
administered therapeutics (55). Nevertheless, BBB is intact in
portions where glioma cells infiltrate into the normal brain
tissue, and thus novel strategies will be necessary to overcome
the tight regulation of lymphocyte trafficking into the brain
parenchyma for the success of immunotherapy. From our
discussion of CNS anatomy and T-cell recruitment, it is clear that
the mechanisms by which T-cells enter the brain parenchyma are
complex and require multifaceted considerations of the broader
circumstances in the CNS environment. A deeper understanding
of the mechanisms underlying T-cell recruitment, especially as it
pertains to the heterogeneous settings of malignant glioma, will
be required for the development of safe and effective genetically
engineered T-cell therapies.
Strategies to Overcome the Unique
Neuroanatomical Challenges of the Brain
Regional Delivery
To circumvent the difficulties of CAR T-cell trafficking into the
brain parenchyma and to reduce systemic toxicity associated
with intravenous delivery, several investigators have initiated
clinical trials to study the safety and efficacy of regional
delivery of CAR T-cells (Figure 2). Regional delivery has been
attempted to improve CAR T-cell localization in ovarian cancer,
mesothelioma, lung cancer, breast cancer, and squamous cell
cancer of the head and neck (NCT02498912, NCT02414269,
NCT01818323). Several authors have established the safety and
efficacy of intracranial or intrathecal delivery of EGFRvIII and
IL13Rα2 CAR T-cells in preclinical models of GBM. Currently,
there have been three clinical trials using regional delivery of
CAR T- cells as an approach to compensate for poor T-cell
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FIGURE 1 | T-cell migration across the blood brain barrier in GBM.
homing and reduce systemic toxicity (25, 26, 56, 57). Yaghoubi
et al. treated a GBM patient via intracranial delivery of IL12Rα2-
specific CAR T-cells after resection of initial tumor. Tumor
regression was observed and T-cells persisted for more than 5
weeks without adverse effects (56). As discussed prior, Brown and
colleagues have conducted two clinical trials exploring the local
administration of IL-13Rα2 CAR T-cells into GBM patients. In
one patient with multiple lesions with meningeal disseminations,
who received repeated intraventricular administration of IL-
13Rα2 CAR T-cells, persistence of the CAR T-cells was seen in
the CSF for at least 7 days after the last intracranial infusion,
and the patient had a complete response for 7 months before
the tumor recurred. The authors also observed a robust increase
in inflammatory cytokine and chemokine induction in the CSF
after infusion compared to the baseline levels without observable
increase in the peripheral blood (26). Similarly, another ongoing
clinical trial providing autologous peripheral blood mononuclear
cells transduced with EGFRvIII CAR directly into the tumor
site aims to increase the efficacy of CAR therapy and reduce
the systemic off-site effects (NCT03283631). While promising,
it is important to recognize that intra-CSF delivery of CAR T-
cells does not necessarily mean effective delivery to the brain
parenchyma, where most glioma tissues reside. Furthermore,
the post-infusion persistence of transferred T-cells remains to
be elucidated as preclinical studies continue to show varied
results (58). The lack of lymphoid organs in the brain to support
lymphocyte survival may be one of the factors driving this
diminished persistence.
CAR T-Cells Expressing Chemokine Receptors
Efficacy of systemic delivery approaches, such as intravenous
infusion, depends on trafficking of CAR T-cells to the tumor site.
In addition to adhesion molecules that we discussed earlier in
this review, the ability of CAR T-cells to effectively localize to
the tumor site also requires expression of chemokine receptors
corresponding to chemokine ligands expressed by the tumor (59).
Amankulor et al. reported that the T-cell attracting chemokines
CXCL9, CXCL10, CCL2, and CCL12 are downregulated in
isocitrate dehydrogenase (IDH)-mutated gliomas, resulting in
the repression of immune cell infiltration (60). On the other
hand, CCL17 and CCL22, which promote recruitment of CCR4+
T regulatory cells (Tregs), are upregulated in GBM (61).
Interestingly, the expression of CCL2 by some gliomas, which
attracts CD8+ T-cells, has been exploited by investigators for
adoptive T-cell strategies (62, 63). Another way of improving
homing of CAR T-cells to the tumor site is by engineering
CAR T-cells that co-express chemokine receptors (Figure 2). Our
group and others have found that CXCR3, along with its ligands
CXCL9 and CXCL10, plays predominant roles in cytotoxic
lymphocyte trafficking into the glioma tumor site (45, 64, 65).
We have also shown that adjuvant polyinosinic-polycytidylic
acid stabilized with polylysine and carboxymethylcellulose (poly-
ICLC) provided systemically can promote cytotoxic lymphocyte
trafficking into gliomas in an IFN-α and IFN-γ dependent
manner through induction of CXCL10 (44).
Additionally, expression of CXCL12 and its receptors, CXCR4
and CXCR7, in the CNS plays important roles in determining
whether lymphocytes can gain entry in the CNS under normal
and inflammatory conditions. Polarized expression of CXCL12
on the basolateral surface of endothelial cells of the BBB
retains CXCR4 expressing leukocytes in the perivascular space
and prevents extravasation into the CNS parenchyma under
normal conditions (66). During pathological conditions such as
multiple sclerosis, polarized expression of CXCL12 is disrupted
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FIGURE 2 | Strategies for improving the efficacy CAR T cell therapy.
by overexpression on the luminal side of the endothelium,
thereby resulting in enhanced leukocyte trafficking into the
CNS. Klein and colleagues have demonstrated that blockade of
CXCR4 on T-cells could facilitate lymphocyte escape from the
perivascular space into the CNS parenchyma (67). Additionally,
both CXCR4 and CXCR7are highly overexpressed in patient-
derived glioma cells (68, 69) and play a critical role in progression
of the disease (70). While CXCR4 antagonism inhibited GBM
tumor growth in various pre-clinical models (71–73), its
direct role in recruitment of T-cells in GBM is yet to be
determined.
Focused Ultrasound
In addition to strategies intended to enhance homing to the
tumor site, there are therapies aimed at disrupting the BBB
that have yet to be tested in the setting of CAR T-cells.
High intensity focused ultrasound (HIFU) is a thermal ablation
technique that has shown to increase activated TIL migration
into solid tumors including breast, liver, pancreas, kidney and
bone cancer (74–76). While HIFU is shown to disrupt the BBB,
it is also accompanied by some tissue damage (77). Therefore, an
alternative approach entitled Focused Ultrasound (FUS), which
uses intensities similar to diagnostic ultrasounds, is used along
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with microbubbles injected intravenously for regional delivery
of drugs and cytokines into the brain parenchyma (78). Chen
et al. observed an increase in tumor infiltrating lymphocytes
and cytotoxic lymphocytes, in particular, after FUS exposure
in the presence of microbubbles (79). Although promising, the
possibility of using FUS to increase localization of CAR T-cells to
the brain safely needs to be thoroughly researched.
IMMUNOSUPPRESSION IN THE GLIOMA
MICROENVIRONMENT
Tumor Cell Intrinsic Mechanisms
The genomic landscape of glioma is complex and encompasses
structural rearrangements, mutations in signature oncogenes
(EGFR, TP53, etc.), as well as chromosome modifying proteins
such as ATRX and IDH (19). Among patients with LGG or
secondary GBM, mutations within IDH1 and IDH2 have been
reported in 70–80% of cases (80). The single amino acid change
within the isocitrate-binding domain (R132 in IDH1; R140 or
R172 in IDH2) confers a gain-of-function mutation leading to
the accumulation of the oncometabolite 2-hydoxyglutarate and
potential genome-wide epigenetic changes. Our group recently
reported that IDH-mutant glioma cells are able to influence the
tumor immune environment through the suppression of type
1 immune response genes (81). We observed decreased overall
expression and activation of signal transducer and activator of
transcription 1 (STAT1) and significantly lower levels of the
effector T-cell attracting chemokines, such as CXCL10, produced
by IDH-mutant glioma cells. Furthermore, a study by Berghoff
and colleagues reported a significantly lower rate of T-cell
infiltration in IDH-mutant vs. IDH-wildtype gliomas (82). These
studies provide evidence that genetic alterations intrinsic to the
glioma tumor cells are able to alter the cellular composition
of the TME and aid in immune evasion. Therefore, novel
immunotherapeutic approaches need to address the downstream
consequences of tumor cell intrinsic mutations in addition to
targeting tumor antigens.
In addition to genetic mutations, GBM cells display a vast
array of molecular signaling alterations, such as the increased
expression and activation of STAT3 (83). Activation of STAT3
results in dynamic transcriptional changes depending on the
cellular context (84). In GBM, phosphorylated STAT3 (p-STAT3)
has emerged as a major regulator of immune suppression
(85). Treatment of GBM patient-derived myeloid cells with
the p-STAT3 small molecule inhibitor WP1066 resulted in
upregulation of the co-stimulatory molecules CD80 and CD86.
Furthermore, in the presence of WP1066, normally unresponsive
patient T-cells were shown to proliferate when stimulated with
autologous APCs (85). In addition to the immunosuppressive
effects of STAT3 in immune cells, work by Wei and colleagues
demonstrated that GBM-initiating cells have a constitutively
active STAT3 pathway, and that inhibition of STAT3 significantly
diminished the ability of these cancer-initiating cells to suppress
T-cell expansion and induce Treg recruitment (86). Based on
these promising data, WP1066 is being evaluated in a phase I
clinical trial for patients with recurrent GBM and melanoma
patients with brain metastases (NCT01904123). Inhibition
of STAT3 in the GBM microenvironment may significantly
contribute to the efficacy of anti-GBM CAR T-cells, and thus the
outcomes of this and any future STAT3-targeting clinical trials
are highly anticipated.
The cellular arm of the immune system offers a potent,
selective, and durable mechanism of protection through the
tightly regulated interactions of T-cells and the vast array of
peptides presented in the groove of human leukocyte antigen
(HLA) molecules. Cytotoxic CD8+ T-cells depend on HLA class
I- presented peptides for their activation. A major immune
resistance mechanism in GBM is the downregulation of HLA
class I expression on tumor cells (87). In certain cases, expression
of HLA class I can be restored by treatment with IFN-γ; however,
mutations leading to loss of heterozygosity (LOH) of the HLA
class I and beta-2 microglobulin regions can result in irreversible
downregulation of HLA class I. Our group has previously
reported that 41% of analyzed GBM samples showed LOH in
the HLA class I region, and this was significantly associated
with shorter survival in newly diagnosed GBM patients (88).
Downregulation of HLA class I expression can also be the
result of changes to the cellular antigen-processing machinery
which is involved in stabilizing and promoting the cell surface
expression of HLA-I molecules. Tapasin is a protein known to
facilitate the binding of peptides to class I molecules, and in its
absence, the expression of HLA class I is significantly reduced
(89, 90). Thuring et al. reported the significant correlation
between tapasin and both HLA-I expression and GBM patients
survival time (91). While CAR constructs must target surface
antigens, a majority of cancer-specific neoantigens are derived
from intracellular proteins. This certainly gives an advantage
for TCR-based approaches. However, success of TCR-based
approaches will likely require additional therapeutic strategies to
ensure sufficient HLA expression levels in the tumor site.
Secreted Factors in the Tumor
Microenvironment
In addition to tumor cell intrinsic factors, various other
mechanisms have been described that render the GBM
microenvironment exceptionally immunosuppressive. These
include the recruitment of Tregs and suppressive myeloid cells
as well as the upregulation of immune checkpoint molecules
and immunosuppressive cytokines [reviewed in detail (92)].
One approach proposed to counteract the immunosuppressive
microenvironment is the co-expression of cytokines such as
IL-12 and IL-15 by CAR T-cells (93, 94). IL-12 has been
shown to enhance CD8+ T-cell activation and to act on
surrounding innate immune cells by providing a type I
differentiation signal. As a result, pre-clinical models suggest
that tumor antigen-specific T-cells engineered to express IL-
12, survive longer in the tumor milieu and are more effective
at tumor clearance than CAR transgenic T-cells alone (93) As
lack of CAR-T cell persistence in vivo is another recurring
obstacle in both pre-clinical and clinical studies, researchers
have engineered CAR-T cells to express the pro-T cell survival
cytokine IL-15 in an activation-dependent manner. Krenciute
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and colleagues demonstrated that upon recognition of their
cognate antigen, T-cells transduced with IL13Rα2-CAR and IL-
15 upregulated production of IL-15 which enhanced the cells’
effector function and their antiglioma activity in vitro and
in vivo (94).
In addition to utilizing a double transgene strategy, the
authors make use of an anti-IL13Rα2 CAR integrating an
antibody-derived scFv as opposed to the zetakine-based
IL13Rα2-CAR. This scFv-based CAR construct has been
shown to exhibit improved antigen specificity as scFv-based
CAR-T cells were able to recognize and kill IL13Rα2-
expressing but not IL13Rα1-expressing target cells (95).
Despite these therapeutic alterations, the authors reported
that gliomas recurred in their xenograft model displaying
lower expression of IL13Rα2, signifying the critical need that
CAR-T cells promote immune responses against multiple tumor
antigens.
Another hurdle to be overcome by adoptively transferred
CAR T-cells is the high local levels of TGF-β in the
TME of GBM (96). Introducing the dominant negative
TGF-β type II receptor in addition to the CAR construct
when manufacturing CAR T-cells renders them resistant
to the effects of TGF-β and has been shown to enhance
antitumor activity of the T-cells (97, 98). Furthermore, TGF-
β inhibitors and blocking antibodies have been studied
extensively pre-clinically. However, their therapeutic efficacy in
glioma patients remains unconvincing, likely due to low BBB
penetrance, underscoring the possibility that targeting TGF-β
alone might not be sufficient to meaningfully impact disease
progression (99, 100).
Immunosuppressive Myeloid Cells
Myeloid cells constitute the largest subset of glioma immune
infiltrates and can account for up to 50% of the total tumor
mass (101, 102). A particular subset of these cells are known
as myeloid derived suppressor cells (MDSC) and are generally
recognized as a heterogenous population of immature myeloid
cells able to support de novo gliomagenesis and produce pro-
tumorigenic factors within already established tumors (103).
Numerous strategies for MDSC depletion and inhibition have
been developed, such as the use of the non-steroidal anti-
inflammatory drug (NSAID) celecoxib or the administration
of STING (stimulator of IFN genes) agonists (Figure 2).
Our group reported that celecoxib inhibits the production of
prostaglandin E2 thus inhibiting the accumulation of MDSCs
in the tumor microenvironment (104). The use of celecoxib
alone was able to enhance expression of CXCL10 and increase
recruitment of cytotoxic lymphocytes to the tumors in a pre-
clinical glioma model. Additional experiments demonstrated
that intratumoral administration of the STING agonist c-di-
GMP was able to relieve the immunosuppressive effect of
MDSC in vivo (105). As a result of enhanced production
of type I cytokines and chemokines, this treatment increased
T-cell migration to the tumor site and improved overall
survival of tumor-bearing mice. Therefore, the addition of
these and other MDSC modulating strategies to traditional
adoptive T-cell therapies may provide substantial clinical
benefit.
Enhancing CAR T-Cell Function With
Immune Checkpoint Inhibitors
Finally, as discussed earlier in this review, both therapeutically
administered as well as endogenously activated T-cells are subject
to elevated levels of immune checkpoint inhibition in the
tumor microenvironment. Recent studies have suggested that
tumor-infiltrating lymphocytes within GBM have an increased
expression of immune checkpoint molecules such as PD-1,
CTLA-4, LAG3, and TIM-3 (27, 106). Similarly, CAR T-cells have
also been observed to express immune checkpoint molecules
and acquire an exhausted phenotype (107, 108). Upregulation
of molecules such as CTLA-4 and PD-1 on T-cells is a natural
consequence of T-cell activation and serves the purpose of
preventing rampant immune cell reactivity (109). Solid tumors
have been shown to co-opt this immune balance mechanism to
suppress the local activation and proliferation of T-cells. The
ligand for PD-1, PD-L1, is present on both tumor cells and
infiltrating myeloid cells. Although a recent study by Nduom
et al. reported a median PD-L1 expression of 2.8% in their
study of 94 GBM samples, robust induction of PD-L1, which is
presumably due to local IFN-γ production, on GBM tissues was
observed in the recent EGFRvIII-CAR clinical trial (12, 110).
Blockage of CTLA-4 and PD-1 in murine solid tumor models
has led to an increased expression of activation markers by T-
cells, such as IFN-γ, IL-2, perforin, and granzyme; furthermore,
these treatments have resulted in improved trafficking of
activated T-cells to the tumor site (111, 112). While the FDA-
approved checkpoint inhibitors are administered systemically,
specific blockade of checkpoint molecules within the therapeutic
T-cells would mitigate systemic toxicities. Cherkassky et al.
developed CAR-T-cells co-transduced with a dominant-negative
PD-1 receptor lacking all the intracellular signaling domains
(107). Using a pleural mesothelioma model, the authors reported
that CAR-T cells expressing the dominant-negative PD-1
receptor controlled the tumor growth more efficiently than the
control CAR-T cells, owing to their enhanced survival and ability
to evade activation-induced exhaustion. Furthermore, the PD-
L1-PD-1 signaling for immunosuppression may take place not
only the surface of interacting cells, but may also be mediated
by soluble PD-L1 in extracellular vesicles (EVs). A recent report
by Ricklefs et al. suggests that GBM-derived EVs, such as
exosomes and microvesicles inhibit human T-cell activation and
proliferation. This effect correlated with the amount of PD-L1
carried by the EVs and was partially reversed through the use of
an anti-PD-L1 antibody (113). Clinical efforts testing the effects
of anti-PD-1 therapy alone in patients with recurrent GBM failed
to show improved overall survival when compared with other
agents (114) (NCT02017717). However, ongoing clinical trials are
currently evaluating the use of CAR T-cells with built in CTLA-4
and PD-1 blockade, CAR T-cells in combination with anti-PD-
1/PDL1 (115) (NCT03170141, NCT02706405), and the use of
CRISPR/Cas9 to disrupt PD-1 in CAR T-cells (NCT03208556)
with the aim of increasing CAR T-cells efficacy (Figure 2).
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CAR T-Cell Persistence and Antigen
Specific Memory
As the addition of checkpoint inhibitors may not be enough to
re-energize T-cells that are exhausted or drive the persistence
of antigen specific memory T-cells to prevent GBM recurrence
(116), new strategies are being explored to address these
aims. A study by Sengupta and colleagues has investigated
the use of a glycogen synthase kinase 3 (GSK3) inhibitor for
improving expansion and persistence of the CAR T-cells. GSK3
is constitutively active in naïve T-cells and is inactivated briefly
during clonal expansion of the activated T-cell (117). At peak
expansion, GSK3 becomes active and results in clonal contraction
and ultimately death of the activated T-cell (118, 119). The
specific blockade of this protein with small molecule inhibitors
results in T-cell expansion and the generation of memory T-
cells (120, 121). Sengupta and colleagues reported that IL-13Rα2
CAR T-cells treated with a GSK3 inhibitor showed reduced
exhaustion and increased expression of an effector memory
phenotype (CD62Llo/CD45ROhi/CD127+) (122). Based on the
demonstrated protective effects of GSK3 inhibition on activated
T-cells, the authors of this study administered the IL-13Rα2 CAR
T-cells and GSK3 inhibitor to mice bearing subcutaneous GBM
xenografts and demonstrated that mice re-challenged with tumor
after initial clearance did not develop new lesions. Furthermore,
they identified CAR+ effector memory T-cells in the draining
lymph nodes and spleens of these animals at 100 days following
initial CAR administration.
ANTIGEN HETEROGENEITY, ANTIGEN
ESCAPE, AND OFF-TUMOR TOXICITY
Antigen Heterogeneity and Escape in GBM
In addition to being tumor-specific, ideal candidate tumor
antigens must be expressed homogenously on the surface of
a majority of tumor cells to mediate effective tumor killing.
Antigen heterogeneity has been a universal barrier to effective
CAR therapy across cancer types, including in the setting
of CD19-CAR for leukemia and lymphoma (123). GBM is
especially challenging in this regard, as clinical studies for all
major tumor-specific and tumor-associated antigens to date
have observed outgrowth of antigen loss variants due to
substantial heterogeneity within tumors (12, 25–27). Because
of its desirability as a tumor-specific antigen and extensive
characterization, we will focus on EGFRvIII here as a prototypical
example of antigen heterogeneity in GBM.
A variety of EGFRvIII CAR variations have been tested
pre-clinically, with alterations in number as well as type of
co-stimulatory domains and these studies have demonstrated
effective and specific tumor lysis in murine and patient-derived
tumor models (124–129). However, as discussed earlier, the
first clinical study testing a second-generation EGFRvIII CAR
failed to demonstrate efficacy and instead highlighted the strong
adaptive capabilities of GBM cells to escape the surveillance
of CAR T-cells by eliminating or altering antigen expression
over time (12). Pre-clinical studies have also demonstrated that
EGFRvIII seems to evade T-cell based targeting approaches
due to the vast heterogeneity in its expression on tumor cells
(130). Active amplification and rearrangement of EGFR can be
found throughout GBM tumors, regardless of EGFRvIII status.
Moreover, EGFRvIII-positive subpopulations may give rise to
EGFRvIII negative clones which can subsequently re-express
EGFRvIII after undergoing epigenetic modification. The survival
of antigen loss variants and the relative ease of reacquiring
EGFRvIII may contribute to the consistent recurrence of
GBM tumors following EGFRvIII-CAR T-cell therapy. Separate
mechanisms guided by the same principles may underlie antigen
loss and tumor recurrence in the settings of other GBM CAR
antigens.
An important barrier to the pre-clinical evaluation of antigen
loss in EGFRvIII-CAR T-cell therapy has been the absence of
EGFRvIII+ GBM patient-derived cell lines and syngeneic mouse
models that effectively recapitulate the dynamics of EGFRvIII
heterogeneity in patient tumors and allow for accurate prediction
of long-term EGFRvIII-CAR T-cell therapy success in the clinic.
Recently, several groups have sought to overcome this barrier
by engineering novel cell lines and pre-clinical models to better
reproduce the heterogeneous nature of EGFRvIII and some
glioma-associated antigens (24, 131). Similar methodologies will
need to be explored for modeling other candidate antigens
undergoing pre-clinical evaluation for CAR T-cell therapy.
Combinatorial Approaches Utilizing
Tumor-Associated Antigens
Antigenic profiling of GBM has revealed a vast availability
of tumor-associated antigens that may be targetable with
immunotherapy (132), yet development of CARs specific for
those novel antigens is hindered by safety concerns with
regards to systemic and on-target off-tumor toxicity. Several
tumor-associated antigen targets have been exploited for the
development of CAR. Ephrin type A receptor 2 (EphA2), IL-
13Ra2, and HER2 represent promising tumor associated antigens
that have been targeted both pre-clinically and clinically using
CAR T-cell therapy in the setting of GBM (23, 133, 134).
Efficacy for monovalent CAR T-cells targeting each of these
antigens has been established in pre-clinical models (135–138).
Multiple groups have attempted to address the hurdle of antigen
heterogeneity and escape in GBM by engineering combinatorial
approaches that simultaneously target multiple GBM-restricted
antigens at once (Figure 2). Hegde, Grada, and colleagues have
developed a tandemCAR combining the recognition of IL-13Rα2
and HER2, based on mathematical modeling that predicted 90%
tumor killing in GBM patients with this antigen combination
(139, 140). This group went on to demonstrate superior efficacy
in vivo for the tandem CAR (tanCAR) construct over bivalent
CAR targeting the same antigens and observed that, in contrast
to bivalent CAR, IFNγ and IL-2 secretion from tanCAR+ T-cells
was higher than simply an additive effect of two monovalent
CARs (141). Unfortunately, tumors did eventually recur in all
groups after antigen clearance and tanCAR T-cells were shown
to develop comparable increases over time in PD-1 and LAG3,
although not TIM3. Based on the analysis of antigen variability
across GBM patient cell lines, Bielamowicz and colleagues have
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since developed a tri-cistronic CAR transgene encompassing IL-
13Rα2, EphA2, and HER2, which they called universal CAR
(UCAR) (142). The authors reported increased cytolytic potential
for UCAR+ T-cells over bivalent CAR+ T-cells, which was at least
partially due to a smaller and more highly organized immune
synapse. Although using the trivalent UCAR+ T-cells resulted in
significantly increased survival, tumors did recur in some mice
between 40 and 60 days after the first T-cell injection following
loss of all three antigens. Repeated observation of antigen loss
begs the question of how many antigens must be targeted at
once for critical mass to occur and drive the complete remission
of malignant glioma (141). Further combinations of tumor-
associated and tumor-specific antigens remain to be developed
for targeting GBM while preventing acquired immune resistance
in the form of antigen loss.
Mitigating Off-Tumor Toxicity
One of the most important risks associated with CAR T-
cell therapy is on-target off-tumor toxicity, particularly in the
case of T-cells targeting tumor-associated antigens. With the
exception of EGFRvIII, all of the GBM antigens that are
currently being evaluated clinically may be expressed at low-
levels on normal tissues, which can result in substantial toxicity.
The risk of on-target toxicity increases with affinity of the
engineered T-cells to their antigen targets, as well as the potency
of the T-cells and antigen expression level on normal tissues
(143). In a trial of high dose HER2-CAR T-cell for metastatic
colon cancer, one patient died of respiratory failure after low
levels of HER2 were engaged on the lung epithelium, but
subsequent studies using modified and lower affinity HER2-
CAR T-cell have not led to any additional case reports which
suggests that these modifications may improve safety (143,
144). A high avidity TCR engineered to target the melanoma
associated antigen A3 (MAGE-A3) was tested in a Phase I
clinical trial and despite showing strong antitumor effects in
most patients, this treatment led to the death of three of the
patients receiving the highest dose regimens. This TCR was
known to recognize another MAGE-A family member, MAGE-
A12, with 10-fold higher affinity. After the death of these
patients, MAGE-A12 expression was subsequently found on
a subset of neurons in these patients and control brains by
histopathological examination (145); these findings underscore
the need for stringent characterization of CAR binding and
cross-reactivity in normal tissues. Neurotoxicity, characterized by
endothelial activation and increased permeability of the BBB, is
also a concern for CAR therapy as it was observed in a patient
following CD19-CAR T-cell therapy (146). In a pre-clinical
murine model, while CAR T-cells targeting GD2 demonstrated
a marked efficacy in DIPG xenograft models, peritumoral
neuroinflammation during the acute phase of antitumor activity
resulted in hydrocephalus that was lethal in a fraction of
animals (147). Furthermore, fatal encephalitis resulting from
low-level antigen expression on the cerebellum was recently
observed following GD2 ganglioside CAR T-cell therapy for
neuroblastoma (148). Cytokine release syndrome (CRS) is also an
important risk of CAR T-cell therapies that must be managed in
the clinical setting. However, none of the existing published trials
of CAR T-cells targeting GBM antigens have resulted in CRS
or elevated peripheral cytokine levels. Management of off-tumor
effects, neurotoxicity, and the potential of CRS remain essential
considerations in the development of novel CAR T-cell therapy
for human trials.
Several novel approaches have been generated for engineering
CARs to limit off-tumor and systemic toxicities that might
have promising applications in the context of GBM (Figure 2).
One important method that has yet to be explored in CNS
cancers is the introduction of a latent suicide switch such
as inducible caspase-9 (iCASP9) enzyme, which can be used
to direct T-cell apoptosis following the administration of a
small-molecule drug (149). One benefit of this strategy is the
ability to rapidly deplete administered T-cells to resolve cases
of CRS and acute tissue toxicity in the clinical setting. In a
clinical trial utilizing iCASP9+ alloreplete T-cells after stem cell
transplantation where graft vs. host disease was detected, the
administration of a small molecule homodimerizer eliminated
85–95% of circulating T-cells within 30min (150). Employing
such an approach in the CNS will require utilizing small molecule
drugs with ample ability to cross the BBB where prevention of
toxicity to normal brain tissue is warranted. Inhibitory CAR T-
cells (iCARs), which target a tumor antigen but co-express an
off-switch that is stimulated by a normal tissue-derived cognate
antigen, has also been proposed to minimize allogenic CAR
T-cell activation in the context of CD19-CAR (151). Roybal,
Morsut, and colleagues have recently developed a novel system
utilizing a synthetic Notch receptor whose activation drives the
transcription of a second generation CAR (Syn-Notch CAR).The
goal of this circuit is to prevent any CAR T-cell activation
without the separate and sequential engagement of two cognate
antigens which may be derived from either the tumor or the
tissue microenvironment (152, 153). They reported that Syn-
CAR+ T-cells failed to become activated in the absence of
either antigen and demonstrated superior tumor-killing efficacy
over bivalent CAR+ T-cells (153). An alternative strategy to
mitigate off-tumor toxicity is a switch-mediated CAR that uses
an antigen-specific antibody-based molecule which specifically
binds the administered SwitchCAR+ T-cells. The binding of
these antibody-based switches drives immunological synapse
formation between SwtichCAR T-cells and tumor cells in a
dose-dependent manner in xenograft models of CD19+ and
CD20+ hematological malignancies, respectively (154, 155). This
methodology has also been effective in targeting HER2+ breast
cancer (156). Despite the plethora of methods being explored
for CAR engineering for mitigation of on-target off-tumor and
systemic toxicity, these strategies have yet to be evaluated in the
context of GBM.
Comparing Efficacy of CD4+ and CD8+
CAR T-Cell Subsets in Glioma
While most of the clinical trials we have discussed thus far have
used a mixture of CD4+ and CD8+ T-cells (12, 26, 27) or CD8+
T-cells alone (25), there have been recent reports that CD4+ CAR
T-cell subsets, in particular, may promote antitumor efficacy. Pre-
clinical models, including a model of GBM, utilizing CD4+ cells
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transduced with a tumor-specific CAR have been found to aid in
tumor-killing by other T-cell subsets as well as to lyse tumor cells
directly (157, 158). In the setting of CAR T-cell therapy for solid
tumors, the existence of CD4+ subsets has been found to increase
CART-cell activity and persistence in vivo (58, 159). A recent pre-
clinical study directly compared efficacy of a second generation
IL-13Rα2 CAR transduced into patient-derived CD8+ or CD4+
T-cells and found CD4+ CAR T-cells demonstrated enhanced
tumor killing and persistence compared with CD8+ and a mixed
CD4+/CD8+ population in a xenograft model of GBM (159). The
CD4+ CAR T-cells in this study secreted more IFNγ and IL-2
than CD8+ T-cells, while the CD8+ CAR T-cells more readily
began expressing exhaustion markers.
TCR Approaches for Targeting Malignant
Glioma
Because CAR targets are limited to surface expressed antigens,
the abundance of tumor-specific neoantigens derived from
intracellular proteins has driven the development of TCR-based
approaches (Figure 2). The histone H3 position 27 lysine to
methionine substitution (H3.3 K27M) mutation is shared across
70% of diffuse intrinsic pontine glioma (DIPG) patients and a
majority of DMG patients (160). It results in a global decrease
of methylation at H3K27me3 and results in the suppression
of polycomb repressive complex 2 (PRC2) and altered gene
expression (161). Overall survival in DIPG patients with this
mutation is shorter compared with patients harboring wild
type H3.3 (160). We recently identified an HLA-A∗02∗:01-
restricted epitope which includes the H3.3 K27M mutation, and
we cloned cDNA of TCR α- and β-chains from this clone for
transduction into T-cells. In this report, we showed that T-cells
transduced with this TCR specific for H3.3K27M efficiently killed
H3.3K27M+ glioma cells in vitro in an antigen- andHLA-specific
manner (14). Furthermore, these TCR transduced T-cells also
suppressed the progression of intracranial glioma xenografts in
mice when used in adoptive transfer studies. These data are
the basis for an upcoming Phase I clinical trial administering
adoptively transferred T-cells with our transduced H3.3 K27M
TCR. While the H3.3 K27M TCR has been effective in murine
models of H3.3K27M+ malignant glioma, the effectiveness of
TCR approaches in patients may require assurance of HLA
class I expression, as discussed earlier. Nonetheless, this strategy
remains a potent tool for targeting immunogenic epitopes which
are not surface expressed but can be routinely presented by HLA
Class I.
In order to develop effective TCR-based therapeutic
approaches targeting antigenic heterogeneity of malignant
glioma, additional novel tumor-specific neoantigens will need
to be identified. A variety of deep sequencing and in silico
HLA docking approaches have been employed with the aim
of identifying neoantigens that can be effectively targeted by
CAR and TCR approaches (162–164). These immunogenomics
approaches are especially relevant in the context of GBM
as 20–30% of recurrent GBM have been found to exhibit a
hypermutator phenotype and may provide a rich supply of
antigens for achieving complete patient response (162).
Re-discovering Glioma Antigens for CAR
T-Cell Therapy
In addition to EGFRvIII, EphA2, IL-13Ra2, and HER2, several
other tumor-associated antigens have previously been explored
as targets for GBM therapies in preclinical models (165–
167). CD70 is found to be highly expressed in both primary
and recurrent LGG and GBM, particularly in association with
wild-type IDH expression (168). It has been shown to play
an important role in recruiting immunosuppressive myeloid
cells to the tumor microenvironment and CD70-CAR T-cells
have demonstrated remarkable efficacy in patient xenograft
and syngeneic murine tumor models (169). Chondroitin sulfate
proteoglycan 4 (CSPG4) represents another emerging target
for GBM CAR T-cells with high expression of this antigen in
two-thirds of GBM patient specimens with little expression on
normal tissues (170). GBM neurosphere engraftment in nude
mice followed by the infusion of a third generation CSPG4-CAR
T-cell demonstrated lasting efficacy and minimal antigen escape,
at least partially due to the upregulation of CSPG4 on tumor cells
by microglia-derived TNF-α in the tumor microenvironment.
While there is currently a limited number of tumor-specific
antigens being targeted in GBM, this list can be expanded
through the identification and analysis of tumor-specific post-
translational modifications of glioma surface proteins. In
particular, novel glycosylation patterns on proteins expressed by
tumor cells may allow for the specific targeting of these cells, as
in the case of the unique mucin 1 (MUC1) glycoepitopes that are
highly expressed in a variety of cancers (171–173). Adoptively
transferred T-cells stimulated against MUC1 have demonstrated
promising results in clinical trials for breast and ovarian cancers
(174–176). Based on the experience of MUC1, the identification
and targeting of post-translational modifications of surface
expressed proteins may constitute an important strategy for
developing novel CAR T-cell therapies in GBM.
PITFALLS AND OPPORTUNITIES FOR
BUILDING ON GLIOMA IMMUNOTHERAPY
Radiographic Imaging and
Pseudoprogression
In the assessment of treatment response, clinicians rely on
radiographic imaging data to interpret changes in tumor
size and composition (177). In particular, enhanced regions
on contrast-enhanced T1-weighted images are indicative of
changes to BBB permeability resulting from tumor proliferation
and angiogenesis. Recognizing that the mechanisms behind
immunotherapeutic response and recurrence may complicate the
interpretation of radiographic information, the Immunotherapy
Response Assessment in Neuro-oncology Working Group
(iRANO) has proposed new guidelines to facilitate assessment
of immunotherapeutic response and address the issue of
pseudoprogression following immunotherapy (178). Following
treatment with immunotherapy, radiographic lesions may spread
beyond incipient tumor margins and include new distal and
local radiographic lesions. These changes to images after
immunotherapy are inherently ambiguous and may represent
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immune infiltration of TME, worsening tumor burden, or a
mixed pathology. Radiographic pseudoprogression is transient in
nature but can result in the premature termination of potentially
beneficial immunotherapeutic treatments and the skewing of
clinical trials toward potentially less responsive patients if left
unrecognized. iRANO has proposed that clinicians consider
pseudoprogression for any apparent radiographic progression
within the first 6 months following the beginning of an
immunotherapeutic regimen, in the absence of neurological
decline, and that indications of progressive disease is confirmed
only after follow-up imaging session before the patient is
reclassified. Moving forward, there is a considerable need for
alternative imaging techniques to be validated, such as magnetic
resonance spectroscopy (MRS), perfusion and diffusion MRI,
as well as PET scanning for distinguishing tumor progression
from immune infiltration (179–183). In addition to improving
the criteria by which radiographic images are assessed, clinicians
are also encouraged to gather biopsy specimens of lesions
whenever possible in order to rule out pseudoprogression and
ensure that patients are given a full opportunity to benefit from
immunotherapy regimens.
Dexamethasone Administration
While genetically engineered T-cell based immunotherapy is
focused upon the development of strong adaptive responses
against tumor tissue in the CNS, clinical treatment of GBM
often requires the administration of corticosteroids such as
dexamethasone to prevent the onset of neurological symptoms
associated with peritumoral edema (178). In preclinical models,
dexamethasone treatment is associated with a dose-dependent
decrease in lymphocyte infiltration of tumor tissue and the
inhibition of T-cell maturation in the CNS by a suppressive
population of monocytes (184). Furthermore, dexamethasone
treatment can impede the maturation of dendritic cells and
decrease their antigen presentation ability in an already
immunosuppressive tumor environment. While much of
these data are restricted to patients receiving high doses of
corticosteroids, it is clear that the necessary administration of
dexamethasone may present a substantial hurdle to some GBM
patients receiving T-cell based immunotherapy unless these
issues are addressed. Brown and colleagues recently addressed
the question of dexamethasone in CAR T-cell therapy in a
xenograft model of GBM. They found that while high-dose
dexamethasone completely inhibited CAR T-cell antitumor
effects, low-dose dexamethasone did not diminish antitumor
effects mediated by CAR T-cell in mice (185). Dexamethasone
administration will need to be considered on a patient-by-
patient basis and weighed against potential and observed
clinical benefit from immunotherapy. The maximum dose of
dexamethasone that will not undermine therapeutic response to
CAR T-cell therapy remains to be defined in the glioma setting.
Ongoing and prospective CAR T-cell therapies for malignant
gliomas will need to consider alternative ways to manage the
symptoms of progressive disease without corticosteroids, such
as through the use of the anti-angiogenesis antibody-based
drug, bevacizumab. Additional methods may be required to
overcome the immunosuppressive and anti-homing effects of
corticosteroid treatment, including alternative delivery routes,
more potent CAR T-cells, and the combined strategies for
addressing immunosuppressive microenvironment that we have
described.
Lymphodepletion and Cytotoxic Therapy
Even though cyclophosphamide and fludarabine have been
most widely used for lymphodepletive conditioning regimens
prior to CAR T-cell therapies, we focus our discussions on a
possibility for the usage of an alkylating chemotherapy agent,
temozolomide (TMZ), because this is a part of the current
standard-of-care alongside radiotherapy and surgical resection
for patients with malignant glioma (186). As TMZ is a potent
inducer of lymphopenia, it has drawn interest for use as a pre-
conditioning agent before adoptive cell therapy (187–189). It
is currently understood that the induction of lymphopenia is a
necessary precondition for CAR T-cell therapy as it upregulates
and eliminates endogenous competition for homeostatic gamma
chain cytokines, such as IL-7, IL-15, and IL-2, to enhance
CAR T-cell persistence (190), although lymphopenia in GBM
patients treated with standard-of-care TMZ + radiation therapy
did not induce compensatory upregulation of IL-7 or IL-15
(188). Suryadevara and colleagues recently used a pre-clinical
mouse model of GBM treated with EGFRvIII-CAR T-cells to
demonstrate that dose-intensified TMZ lymphodepletion can
durably enhance CAR T-cell efficacy and persistence, while
standard dose TMZ was transient and did not have significantly
different effect from vehicle (189). Furthermore, they showed that
dose-intensified TMZ lymphodepletion significantly increased
the ratio of CAR T-cell:Treg over that with the standard dose
of TMZ. Notably, TMZ and other cytotoxic therapy may be
able to produce synergistic effects with CAR T-cell therapy, and
there is active ongoing research to improve protection of CAR
T-cells from the cytotoxic effects of these therapies (129, 191).
These preclinical studies, however, need careful interpretations
considering the difference in the dose and duration of therapies
between humans and mice.
Conventional fractionated radiotherapy also has a profound
lymphodepleting effect due to the large volume of blood that
perfuses the human brain and can be affected by radiation
(187, 188, 192). It has been associated with the recruitment of
Tregs and MDSC, resulting in increased production of TGF-
β, IL-10, and angiogenic factors in the TME (193). However,
it has been hypothesized that radiotherapy might also play a
positive role for CAR T-cell therapies. Radiotherapy can result
in release of danger signals, such as HMGB1 and HSP70, which
activate the innate and adaptive immune systems, in the context
of GBM cell lines (194, 195). The cytotoxic effects of local
radiotherapy also lead to the phagocytosis of tumor cells, which
in turn can induce maturation of dendritic cells and enhance
presentation of tumor antigens (196). In murine models, whole
brain radiotherapy resulted in upregulation of MHC Class I and
increased infiltration of CD8+ and CD4+ T-cells into the tumor
microenvironment (197), although murine models do not allow
recapitalization of fractionated radiation therapy in humans.
Radiotherapy has been explored extensively (198) in combination
with checkpoint blockade but relatively little in the area of CAR
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T-cells. However, Weiss and colleagues recently developed an
NKG2D-based CART-cell for use in a preclinical mousemodel of
GBM and demonstrated improved efficacy and persistence when
CAR T-cell therapy was combined with sub-therapeutic dosages
of radiotherapy (199). They concluded this synergistic effect was a
result of NKG2D ligands released in the TME following radiation.
Importantly, while the authors did not observe any off-tumor
toxicity, NKG2D ligand expression is not restricted to GBM
tissue and could theoretically result in toxicity. As is the case for
TMZ, careful interpretation of these preclinical studies is needed
considering the relatively short duration of therapy regimens in
mice.
CONCLUSION
Glioma immunotherapy continues to present unique challenges
due to anatomical barriers associated with the CNS and the
intrinsic danger of eliciting an immune response in close
proximity to neural tissue. In this review, we have discussed
the most recent clinical outcomes utilizing CAR T-cells to
target glioma, as well as the strategies being explored to
address emerging impediments to these treatments. Limited
engraftment and survival of the infused T-cells due to difficulty
homing to the tumor site is a substantial problem in genetically
engineered T-cell therapies for malignant glioma. Complex
anatomical barriers make drainage of antigens and immune
cells from the brain parenchyma into the periphery difficult and
may mitigate peripheral lymphocyte activation against tumor
antigens. Moreover, the homing of T-cells is limited by the
BBB and an immunosuppressive TME. Altering the expression
patterns of chemokines and their receptors in an effort to enhance
T-cell homing to the brain tumor site have shown promise in
pre-clinical studies, but these remain to be tested in the clinical
setting.
In addition, the heterogeneous display of tumor antigens
has resulted in tumor escape and recurrence of malignant
gliomas. However, as additional tumor-associated antigens
are explored for combined targeting, concerns about on-
target off-tumor and systemic toxicities are warranted. Creative
solutions to the combined challenges of safety and antigen
heterogeneity have emerged in recent pre-clinical studies, as
discussed in this review. In addition to enhancing the CAR
T-cells efficacy against multiple tumor antigens, mounting
evidence supports the need for combining engineered T-
cells with modulators of the highly immunosuppressive TME.
Recent data discussed here clearly suggest a potential for
synergy of CAR T-cells with other treatments targeting the
mechanisms of glioma immunosuppression. In addition to
these combined strategies, engineering CAR T-cells which also
express pro-survival cytokines may aid in overcoming local
immunosuppression.
Several questions remain regarding the optimal delivery
method and post-treatment care of GBM patients. Another
challenge for clinicians designing and executing GBM
clinical trials remains the administration of corticosteroids
as means of avoiding the neurological symptoms of edema. The
establishment of corticosteroid dosing guidelines for glioma
patients receiving T-cell therapies, and the consideration of
alternative interventions are likely to maximize the efficacy
of CAR T-cells in the clinical setting. Despite the number of
hurdles facing the use of genetically engineered T-cells for glioma
immunotherapy, novel pre-clinical strategies addressing each
of these hurdles continue to present opportunities for clinical
progress. Creative and mindful bioengineers will need to work
closely with clinical and surgical experts in order to drive forward
the field of immune-oncology, both on the bench and at the
bedside.
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